Condition: Berger Disease · Bergers Disease · IgA Nephropathy · Sponsor: Novartis Pharmaceuticals
A Phase III, single-arm, multicenter pediatric clinical study evaluating atrasentan in children and adolescents aged 2 to \<18 years with primary immunoglobulin A nephropathy (IgAN).
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111
Always discuss trial participation with your own doctor first.
| Hackensack Meridian Health | Neptune City, New Jersey, United States | Not Yet Recruiting |
| Cincinnati Childrens Hospital MC | Cincinnati, Ohio, United States | Not Yet Recruiting |
| University of Oklahoma Health Science Center | Oklahoma City, Oklahoma, United States | Not Yet Recruiting |
| University of Tennessee Health Science Center- Le Bonheur Research Center | Memphis, Tennessee, United States | Not Yet Recruiting |
| Novartis Investigative Site | Nagoya, Aichi-ken, Japan | Recruiting |
| Novartis Investigative Site | Fukuoka, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07498335